Neuropharmacology & Neurotherapeutics
Chelation therapy [Archived]
Mar. 26, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Age- and sex-adjusted subhazard ratio (sHR) in patients with Wernicke-Korsakoff syndrome (WKS) and alcohol-related dementia (ARD) compared with antipsychotic non-users, stratified by causes of death (ICD-10 diagnosis groups). The value for antipsychotic non-users is represented by the dotted line (ie, the line extending vertically from 1 on the x-axis). A competing risks regression model was used to calculate age- and sex-adjusted subhazard ratios, where other causes of death were considered competing risks. (Source: Palm A, Talaslahti T, Vataja R, et al. Antipsychotic use and mortality in persons with alcohol-related dementia or Wernicke-Korsakoff syndrome: a nationwide register study in Finland. J Clin Med 2023;12[13]:4263. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)